Research and Clinical Trials

Brief Description  
Primary aim of this Phase III randomized clinical trial is to determine whether trastuzumab given along with radiation therapy (RT) is more beneficial in preventing breast cancer from recurring in affected side, skin cancer from recurring in affected side (ipsilateral), or ipsilateral DCIS , when compared with RT alone in women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy. Submission of a representative tumor block for central HER2 testing is required prior to ra
Who may be Eligible  
Women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy. Pre-entry central HER2 testing is required for all patients. Patients must be 18 years of age or older On histologic examination, the tumor must be ductal carcinoma in situ (DCIS). (Patients with mixed DCIS and lobular carcinoma in situ [LCIS] are eligible.)
Speciality/Disorder  
Breast cancer
IRB Number  
04-09-02A
Principal Investigator  
Limentani, Steven

For More Information, Contact  Amy  J, Yeh
Phone:  (704) 355-1672  Fax:  (704) 355-1353  
Email:  amy.yeh@carolinashealthcare.org
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203
Close